Anti-inflammatory properties of C-peptide

Review of Diabetic Studies

Volumn 6, Issue 3, 2009, Pages 168-179

  Haidet, Jaime ^a   Cifarelli, Vincenza ^a   Trucco, Massimo ^a   Luppi, Patrizia ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

C peptide; Endothelial dysfunction; Inflammation; NF B; Type 1 diabetes; Vascular smooth muscle cells

Indexed keywords

C PEPTIDE; CELL ADHESION MOLECULE; CYTOKINE; GLUCOSE; INSULIN;

ANTIINFLAMMATORY ACTIVITY; BRAIN DISEASE; CELL INTERACTION; CYTOKINE PRODUCTION; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERNALIZATION; LEUKOCYTE ADHERENCE; NONHUMAN; PATHOGENESIS; REVIEW; SEPTIC SHOCK; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

EID: 76149122484     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2009.6.168     Document Type: Review

References (101)

1. Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, Kuzuya H, Horwitz DL, Rubenstein AH, Rossing N. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 1978. 62(1):197-203.
2. Melles E, Bergman T, Alvelius G, Jonsson A, Ekberg K, Wahren J, Jornvall H. Proinsulin C-peptide and its C-terminal pentapeptide: degradation in human serum and Schiff base formation with subsequent CO2 incorporation. Cell Mol Life Sci 2003. 60(5):1019-1025.
3. Kamiya H, Zhang W, Ekberg K, Wahren J, Sima AA. C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes 2006. 55(12):3581-3587.
4. Ekberg K, Brismar T, Johansson BL, Lindstrom P, Juntti-Berggren L, Norrby A, Berne C, Arnqvist HJ, Bolinder J, Wahren J. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007. 30(1):71-76.
5. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000. 17(3):181-189.
6. Sima AA, Zhang W, Li ZG, Kamiya H. The effects of C-peptide on type 1 diabetic polyneuropathies and encephalopathy in the BB/Wor-rat. Exp Diabetes Res 2008. 2008:230458.
7. Kamiya H, Zhang W, Sima AA. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 2004. 56(6):827-835.
8. Pierson CR, Zhang W, Sima AA. Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration. J Neuropathol Exp Neurol 2003. 62(7):765-779.
9. Cifarelli V, Luppi P, Tse HM, He J, Piganelli J, Trucco M. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis 2008. 201(2):248-257.
10. Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Diabetologia 2008. 51(8):1534-1543.
11. Sima AA, Zhang W, Kreipke CW, Rafols JA, Hoffman WH. Inflammation in diabetic encephalopathy is prevented by C-peptide. Rev Diabet Stud 2009. 6(1):37-42.
12. Vish MG, Mangeshkar P, Piraino G, Denenberg A, Hake PW, O'Connor M, Zingarelli B. Proinsulin cpeptide exerts beneficial effects in endotoxic shock in mice. Crit Care Med 2007. 35(5):1348-1355.
13. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, et al. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on ardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 2005. 111(25):3489-3493.
14. Andresen JL, Rasmussen LM, Ledet T. Diabetic macroangiopathy and atherosclerosis. Diabetes 1996. 45(Suppl 3):S91-S94.
15. Jarvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, Laine S, Lehtimaki T, Ronnemaa T, Viikari J, Raitakari OT. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004. 109(14):1750-1755.
16. Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallen NH. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004. 47(3):537-540.
17. Clausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rasmussen B. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy. Diabet Med 2000. 17(9):644-649.
18. Jude EB, Douglas JT, Anderson SG, Young MJ, Boulton AJ. Circulating cellular adhesion molecules ICAM-1, VCAM-1, P- and E-selectin in the prediction of cardiovascular disease in diabetes mellitus. Eur J Intern Med 2002. 13(3):185-189.
19. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003. 26(7):2165-2173.
20. Lampeter ER, Kishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, Kolb H, Martin S. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 1992. 41(12):1668-1671.
21. Ribau JC, Hadcock SJ, Teoh K, DeReske M, Richardson M. Endothelial adhesion molecule expression is enhanced in the aorta and internal mammary artery of diabetic patients. J Surg Res 1999. 85(2):225-233.
22. Schmidt AM, Crandall J, Hori O, Cao R, Lakatta E. Elevated plasma levels of vascular cell adhesion molecule-1 (VCAM-1) in diabetic patients with microalbuminuria: a marker of vascular dysfunction and progressive vascular disease. Br J Haematol 1996. 92(3):747-750.
23. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand 2001. 173(1):35-43.
24. Elhadd TA, Kennedy G, Hill A, McLaren M, Newton RW, Greene SA, Belch JJ. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev 1999. 15(6):405-411.
25. Dogruel N, Kirel B, Akgun Y, Us T. Serum soluble endothelial-cell specific adhesion molecules in children with insulin-dependent diabetes mellitus. J Pediatr Endocrinol Metab 2001. 14(3):287-293.
26. Toivonen A, Kulmala P, Rahko J, Ilonen J, Knip M. Soluble adhesion molecules in Finnish schoolchildren with signs of preclinical type 1 diabetes. Diabetes Metab Res Rev 2004. 20(1):48-54.
27. Toivonen A, Kulmala P, Savola K, Akerblom HK, Knip M, The Childhood Diabetes In F. Soluble adhesion molecules in preclinical type 1 diabetes. The Childhood Diabetes in Finland Study Group. Pediatr Res 2001. 49(1):24-29.
28. Toivonen AM, Kimpimaki T, Kupila A, Korhonen S, Hyoty H, Virtanen SM, Ilonen J, Simell O, Knip M. Soluble adhesion molecules in young children with signs of beta-cell autoimmunity - prospective follow-up from birth. Diabetes Metab Res Rev 2006. 22(3):176-183.
29. Toivonen AM, Kulmala P, Savola K, Akerblom HK, Knip M. Soluble adhesion molecules in pre-clinical Type 1 diabetes: a prospective study. Diabetologia 2003. 46(4):492-495.
30. Baumgartner-Parzer SM, Wagner L, Pettermann M, Gessl A, Waldhausl W. Modulation by high glucose of adhesion molecule expression in cultured endothelial cells. Diabetologia 1995. 38(11):1367-1370.
31. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995. 96(3):1395-1403.
32. Rasmussen LM, Schmitz O, Ledet T. Increased expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured endothelial cells exposed to serum from type 1 diabetic patients: no effects of high glucose concentrations. Scand J Clin Lab Invest 2002. 62(7):485-493.
33. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993. 328(23):1676-1685.
34. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997. 100(9):2153-2157.
35. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004. 53(8):2060-2066.
36. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999. 48(10):1899-1906.
37. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001. 414(6865):813-820.
38. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996. 19(3):257-267.
39. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000. 404(6779):787-790.
40. Ceriello A, dello Russo P, Amstad P, Cerutti P. High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes 1996. 45(4):471-477.
41. Cohen RA. Pathways controlling healthy and diseased arterial smooth muscle. Am J Cardiol 1993. 72(8):39C-46C.
42. Du X, Stocklauser-Farber K, Rosen P. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic Biol Med 1999. 27(7-8):752-763.
43. Kado S, Wakatsuki T, Yamamoto M, Nagata N. Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. Life Sci 2001. 68(7):727-737.
44. Kim JA, Berliner JA, Natarajan RD, Nadler JL. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 1994. 43(9):1103-1107.
45. Piga R, Naito Y, Kokura S, Handa O, Yoshikawa T. Short-term high glucose exposure induces monocyteendothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007. 193(2):328-334.
46. Srinivasan S, Yeh M, Danziger EC, Hatley ME, Riggan AE, Leitinger N, Berliner JA, Hedrick CC. Glucose regulates monocyte adhesion through endothelial production of interleukin-8. Circ Res 2003. 92(4):371-377.
47. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA, Jr., Luster AD, Luscinskas FW, Rosenzweig A. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999. 398(6729):718-723.
48. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1994. 1(Suppl 1):S10-S13.
49. Flier JS. Diabetes. The missing link with obesity? Nature 2001. 409(6818):292-293.
50. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 2003. 26(10):2871-2875.
51. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993. 329(14):977-986.
52. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998. 128(7):517-523.
53. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 2003. 46(10):1402-1407.
54. Schalkwijk CG, Ter Wee PM, Stehouwer CD. Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate: possible role of AGE peptide-associated endothelial dysfunction. Ann N Y Acad Sci 2005. 1043:662-670.
55. Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, Aoki T. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 2007. 56(11):2790-2796.
56. Cifarelli V, Libman IM, Deluca A, Becker D, Trucco M, Luppi P. Increased Expression of Monocyte CD11b (Mac-1) in Overweight Recent-Onset Type 1 Diabetic Children. Rev Diabet Stud 2007. 4(2):112-117.
57. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker DS, She JX, Hofig A, Dennis MA, Fuller K, Cook R, et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulindependent diabetes mellitus. J Clin Invest 1999. 104(4):515-523.
58. Beyan H, Goodier MR, Nawroly NS, Hawa MI, Bustin SA, Ogunkolade WB, Londei M, Yousaf N, Leslie RD. Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Diabetes 2006. 55(12):3439-3445.
59. Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. Br J Ophthalmol 2004. 88(10):1343-1347.
60. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003. 34(12):1563-1574.
61. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet 1996. 347(8999):444-445.
62. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 1989. 257(1 Pt 2):H33-H37.
63. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986. 250(5 Pt 2):H822-H827.
64. Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med 2000. 28(9):1317-1327.
65. Soares MP, Muniappan A, Kaczmarek E, Koziak K, Wrighton CJ, Steinhauslin F, Ferran C, Winkler H, Bach FH, Anrather J. Adenovirus-mediated expression of a dominant negative mutant of p65/RelA inhibits proinflammatory gene expression in endothelial cells without sensitizing to apoptosis. J Immunol 1998. 161(9):4572-4582.
66. Zuckerbraun BS, McCloskey CA, Mahidhara RS, Kim PK, Taylor BS, Tzeng E. Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation. J Vasc Surg 2003. 38(4):812-819.
67. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997. 3(8):894-899.
68. Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O, Grassi G, Cavallo-Perin P, Bruno G. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009. 32(2):301-305.
69. Hansen A, Johansson BL, Wahren J, von Bibra H. Cpeptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 2002. 51(10):3077-3082.
70. Gerrity RG. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am J Pathol 1981. 103(2):191-200.
71. Scalia R, Coyle KM, Levine BJ, Booth G, Lefer AM. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. Faseb J 2000. 14(14):2357-2364.
72. Young LH, Ikeda Y, Scalia R, Lefer AM. C-peptide exerts cardioprotective effects in myocardial ischemiareperfusion. Am J Physiol Heart Circ Physiol 2000. 279(4):H1453-H1459.
73. Lee RT, Yamamoto C, Feng Y, Potter-Perigo S, Briggs WH, Landschulz KT, Turi TG, Thompson JF, Libby P, Wight TN. Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. J Biol Chem 2001. 276(17):13847-13851.
74. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999. 340(2):115-126.
75. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009. 53(5 Suppl):S35-S42.
76. Nakamura J, Kasuya Y, Hamada Y, Nakashima E, Naruse K, Yasuda Y, Kato K, Hotta N. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia 2001. 44(4):480-487.
77. Natarajan R, Gonzales N, Xu L, Nadler JL. Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem Biophys Res Commun 1992. 187(1):552-560.
78. Yamamoto M, Acevedo-Duncan M, Chalfant CE, Patel NA, Watson JE, Cooper DR. Acute glucoseinduced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol 2000. 279(3):C587-C595.
79. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988. 242(4878):540-546.
80. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 1997. 82(2):297-304.
81. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999. 48(4):855-864.
82. Autieri MV, Yue TL, Ferstein GZ, Ohlstein E. Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun 1995. 213(3):827-836.
83. Mehrhof FB, Schmidt-Ullrich R, Dietz R, Scheidereit C. Regulation of vascular smooth muscle cell proliferation: role of NF-kappaB revisited. Circ Res 2005. 96(9):958-964.
84. Dragomir E, Manduteanu I, Calin M, Gan AM, Stan D, Koenen RR, Weber C, Simionescu M. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb Haemost 2008. 100(6):1155-1165.
85. Kanellakis P, Pomilio G, Walker C, Husband A, Huang JL, Nestel P, Agrotis A, Bobik A. A novel antioxidant 3,7-dihydroxy-isoflav-3-ene (DHIF) inhibits neointimal hyperplasia after vessel injury attenuating reactive oxygen species and nuclear factor-kappaB signaling. Atherosclerosis 2009. 204(1):66-72.
86. Radhakrishnan G, Suzuki R, Maeda H, Yamamoto M, Hirose N, Gopalrao RK, Lee GH, Hayashi Y, Rao P, Sasaguri S. Inhibition of neointimal hyperplasia development by MCI-186 is correlated with downregulation of nuclear factor-kappaB pathway. Circ J 2008. 72(5):800-806.
87. Kobayashi Y, Naruse K, Hamada Y, Nakashima E, Kato K, Akiyama N, Kamiya H, Watarai A, Nakae M, Oiso Y, et al. Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia 2005. 48(11):2396-2401.
88. Walcher D, Babiak C, Poletek P, Rosenkranz S, Bach H, Betz S, Durst R, Grub M, Hombach V, Strong J, et al. C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res 2006. 99(11):1181-1187.
89. Li ZG, Zhang W, Grunberger G, Sima AA. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res 2002. 946(2):221-231.
90. Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes 2005. 54(5):1497-1505.
91. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003. 168(2):165-172.
92. Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). Jama 1992. 268(24):3452-3455.
93. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004. 32(3):858-873.
94. Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath WF, DiMarchi RD, Di Cera E, Williamson JR. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997. 277(5325):563-566.
95. Flatt PR, Swanston-Flatt SK, Hampton SM, Bailey CJ, Marks V. Specific binding of the C-peptide of proinsulin to cultured B-cells from a transplantable rat islet cell tumor. Biosci Rep 1986. 6(2):193-199.
96. Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson OT, Nygren P, Stahl S, Ekberg K, Johansson B, Uhlen S, et al. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A 1999. 96(23):13318-13323.
97. Grunberger G, Sima AA. The C-peptide signaling. Exp Diabesity Res 2004. 5(1):25-36.
98. Pramanik A, Ekberg K, Zhong Z, Shafqat J, Henriksson M, Jansson O, Tibell A, Tally M, Wahren J, Jornvall H, et al. C-peptide binding to human cell membranes: importance of Glu27. Biochem Biophys Res Commun 2001. 284(1):94-98.
99. Lindahl E, Nyman U, Melles E, Sigmundsson K, Stahlberg M, Wahren J, Obrink B, Shafqat J, Joseph B, Jornvall H. Cellular internalization of proinsulin Cpeptide. Cell Mol Life Sci 2007. 64(4):479-486.
100. Luppi P, Geng X, Cifarelli V, Drain P, Trucco M. Cpeptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes. Diabetologia 2009. 52(10):2218-2228.
101. Miaczynska M, Pelkmans L, Zerial M. Not just a sink: endosomes in control of signal transduction. Curr Opin Cell Biol 2004. 16(4):400-406.